Baricitinib, an oral selective inhibitor of JAK1 and JAK2, proved to be safe and effective at the dose of 4 mg in the resolution of arthritis or rash at week 24 in combination with standard of care in a phase 2 RCT of 314 SLE patients.51 In this trial, baricitinib reduced anti-dsDNA titres, and other pro-inflammatory cytokines.52,53 In SLE-BRAVE 1, a phase 3 RCT, 760 patients were randomly assigned to receive baricitinib 4mg, 2mg, or placebo.54 This evidence concerns the gene JAK1 and systemic lupus erythematosus.